News

News of Cell Point Web

Cell>Point enters into license agreement with Vyripharm Biopharmaceuticals for the use of Cell>Point’s In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology

CENTENNIAL, Colo., August 24, 2016  – Cell>Point today announced it has entered into license
agreements with Vyripharm Biopharmaceuticals for the use of its In-Situ Hydrogel, N4 Technology and
Oligosaccharide (Dual Agent) Technology to develop applications in combination with cannabinoids for
nuclear imaging and therapeutic applications for neurologic disorders including, but not limited to, posttraumatic
stress disorder (“PTSD”), epilepsy and other acute/chronic disorders. As part of the license
Cell>Point will own a majority interest in Vyripharm Biopharmaceuticals.

About Cell>Point, L.L.C.

Cell>Point is a biopharmaceutical company focused on the development of universal molecular imaging compounds and molecular therapeutics for the diagnosis, staging, treatment and treatment monitoring of cancer, cardiovascular disease, and a range of ischemic diseases. Cell>Point has exclusive licenses to five drug-development platforms, all from The University of Texas MD Anderson Cancer Center in Houston, a world leader in cancer research and care. Information on Cell>Point’s product candidates and licenses, recent press releases, and patents and patent filings can be obtained through its website at www.cellpointweb.com. The Company has offices in Centennial, Colo. and Houston, Texas.

About Vyripharm Biopharmaceuticals, L.L.C

Vyripharm Biopharmaceuticals is a Delaware limited liability company formed in 2014 for the purpose of treating neurological disorders and cancers. The Company has established a proprietary comprehensive analytical testing, monitoring and tracking system program that it believes will become the standard accepted methodology to help create stability and predictability in the emerging business of medical cannabinoids. The Company will also develop applications (using in-licensed proprietary technologies in combination with cannabinoids) for nuclear imaging and therapeutic applications for neurologic disorders including, but not limited to, post-traumatic stress disorder (“PTSD”), epilepsy and other acute/chronic disorders. The company is located in Houston, Texas.

Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia for Cancer and Heart Disease Diagnostic Imaging

CENTENNIAL, Colo., June 16, 2016 – Cell>Point today announced that it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the U.S. and China.

The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia (ethylenedicysteine-glucosamine) which was developed for labeling with technetium-99m for SPECT cameras or 68-gallium for PET cameras for imaging in cancer and cardiovascular disease. Oncardia is based on an ethylenedicysteine drug conjugate platform licensed by Cell>Point from The University of Texas M.D. Anderson Cancer Center. The license with UEP provides for Cell>Point to receive an upfront payment, regulatory milestone payments as well as royalties on sales. Cell>Point will be seeking regulatory approval from the China FDA to expand its Phase 3 lung cancer imaging trial to include clinical sites in China. The parties have agreed that when the current cardiovascular study reaches Phase 3, Cell>Point will include China clinical sites as part of the study.

According to Haoran Xi, CEO of UEP, “China needs affordable and accessible diagnostic molecular imaging to reach a substantially larger universe of people than is presently the case with the current standard of care. Plans are to pursue approvals in diagnosing and staging lung, head and neck, colorectal, breast, liver, stomach, lymphoma and other cancers in addition to diagnosing the presence and extent of cardiac ischemia. Oncardia can be used to assess the patient’s response to therapy while undergoing therapy. This will give oncologists a valuable tool to determine if the patient is benefiting from the selected therapy or should the oncologist reconsider the choice of therapy. The Chinese Central Government is implementing programs to improve the quality of medical care throughout the country. Cancer and vascular disease are the leading causes of death in China.”

Oncardia was developed to address the limitations of FDG-PET in cancer imaging while increasing access to cancer imaging to a significantly greater number of hospitals worldwide. Cell>Point is completing a Phase 3 trial for Oncardia in lung cancer under a Letter of Agreement with the FDA pursuant to a Special Protocol Assessment, and a Phase 2b cardiovascular trial in patients with coronary artery disease. The focus in cardiology is to assess the patient’s ischemia in a rest only imaging procedure which will
dramatically shorten the time required to complete the patient’s study and achieve noticeably greater diagnostic accuracy compared to the standard of care. “We are pleased to be working with UEP as our long term partner in China and are confident that UEP will be instrumental in helping to build a consensus of support for Oncardia among the country’s nuclear medicine community and network of hospitals”, according to Greg Colip, CEO of Cell>Point.

About Cell>Point, L.L.C.

Cell>Point is a biopharmaceutical company focused on the development of universal molecular imaging compounds and molecular therapeutics for the diagnosis, staging, treatment and treatment monitoring of cancer, cardiovascular disease, and a range of ischemic diseases. Cell>Point has exclusive licenses to five drug-development platforms, all from The University of Texas MD Anderson Cancer Center in Houston, a world leader in cancer research and care. Information on Cell>Point’s product candidates and licenses, recent press releases, and patents and patent filings can be obtained through its website at www.cellpointweb.com. The Company has offices in Centennial, Colo. and Houston, Texas.
About United Eastern Pharmaceutical

United Eastern Pharmaceutical (UEP), formerly TDD, Inc., is a Houston, Texas based cross-industry group whose focus is investment in energy and pharmaceutical development. UEP, together with a consortium of partners based in Tianjin, will be responsible for the clinical development, regulatory approval, marketing and distribution in China (including Hong Kong and Macau) of Cell>Point’s novel nuclear medicine imaging product Oncardia for cancer and cardiovascular disease.

Cell>Point Announces Postive Results from 99mTc-Oncardia (EC- G) trial at the Unviersity of Chicago Medical Center to image and montior therapy for Head and Neck Cacer.

CENTENNIAL, Colo., January 15, 2015 – Cell>Point announced today positive results following conclusion of a Head and Neck Cancer imaging trial for <sup>99m</sup>Tc-Oncardia conducted pursuant to a  physician initiated IND study at the University of Chicago Medical Center.

The study imaged patients with squamous cell carcinoma of the head and neck (SCCHN) with technetium-99m- labeled Oncardia (Ethylenedicysteine-Glucosamine), Cell>Point’s proprietary nuclear imaging product candidate.   The purpose of the study was to evaluate and study treatment response for patients with SCCHN.  Patients were  imaged prior to starting therapy and at 4 and 10 weeks.  <sup>99m</sup>Tc-Oncardia, as imaged by SPECT/CT, correctly localized  in the SCCHN tumor prior to treatment and images at 4 and 10 weeks properly reflected treatment.   Cell>Point  believes 99mTc-Oncardia will offer better specificity and better predictive values than those achievable from other  imaging modalities in assessing therapeutic response for those patients with locally and advanced head and neck  cancer.

Please see attached poster presentation on preliminary results from The University of Chicago.

About Cell>Point

Cell>Point is a commercialization-stage biopharmaceutical company developing universal molecular imaging agents and molecular therapeutics for the diagnosis, treatment and treatment monitoring of cancer, heart disease,  and other diseases. Information on Cell>Point’s product candidates and licenses, recent press releases, and  patents and patent filings can be obtained through its website at www.cellpointweb.com. The Company has offices  in Centennial, Colo. and Houston, Texas.

Cell>Point Announces Encouraging Results from 99mTc -EC-G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease

CENTENNIAL, Colo., April 9, 2013—Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri.

The study imaged patients with technetium-99m-labeled Ethylenedicysteine-Glucosamine (99mTc-EC-G), Cell>Point’s proprietary nuclear imaging product candidate, which is target specific for detecting the presence and extent of  schemia in patients with Coronary Artery Disease (CAD).

The results from the Phase 1 and 2a studies show that 99mTc-EC-G has the potential to accurately diagnose myocardial ischemia (that is, decrease in blood flow and oxygen to heart muscle) in as little as 30 minutes post injection in patients studied at rest only.

“Based on what we have observed in clinical data for Phase 1 and Phase 2a, and assuming further confirmation in Phase 2b, it is our belief that 99mTc-EC-G has the ability to dramatically shift the paradigm for nuclear cardiac imaging in terms of significantly shortening procedure time, increasing diagnostic accuracy, and easing the patient’s experience by eliminating the need in most cases for a separate stress study,” said Cell>Point President David Rollo, M.D., Ph.D.

The multicenter Phase 2b trial will evaluate the diagnostic accuracy (sensitivity and specificity) of a 99mTc-EC-G study performed at rest only compared to a two-day 99mTc-Cardiolite rest/stress study to determine the presence, anatomical location, and severity of ischemia in patients with CAD. Diagnostic catheterization will be used as the standard of truth. Camargo Pharmaceutical Services of Cincinnati will perform the role of general manager over the clinical research and regulatory function for the study. Premier Research of Research Triangle Park, North Carolina, will continue their role as the clinical research organization for the study.

Leading the Phase 2b study as principal investigator will be Gary Heller, M.D., Ph.D., Professor of Medicine and Nuclear Medicine at the University of Connecticut School of Medicine, and a world renowned nuclear cardiologist who has authored several hundred clinical articles and a number of textbooks in nuclear cardiology.

According to the American Heart Association, over 10 million nuclear cardiology scans are performed annually in the United States. Over 90 percent of the scans are Myocardial Perfusion Imaging (MPI) procedures, a $1.8 billion U.S. market.

A typical MPI procedure, which comprises both a rest and stress study, takes between 5 and 7 hours to complete. For the stress component of the MPI study, patients are subjected to physical and/or pharmacologic stress, which is often an issue and an inconvenience for the patient. Because of the required time separation between the stress and rest study, the patient is typically asked to return the next day to complete the full study. This significantly increases the time commitment for the patient and further restricts camera availability for additional patient studies. It is one of Cell>Point’s goals with 99mTc-EC-G to substantially reduce the need for the patient to undergo a stress study, thus positively impacting the patient’s time commitment as well as camera access for additional nuclear cardiac imaging studies.

About Cell>Point

Cell>Point is a commercialization-stage biopharmaceutical company developing universal molecular imaging agents and molecular therapeutics for the diagnosis, treatment and treatment monitoring of cancer, heart disease, and other diseases. Cell>Point has exclusive license to five drug-development platforms, all from The University of TexasMD Anderson Cancer Center in Houston, a world leader in cancer research and care. With the platforms, Cell>Point has created a robust pipeline covering cancer imaging and therapy; cardiovascular imaging; high-yield radio/chemotherapy delivery system for treating inoperable and unresectable tumors; neuroendocrine disease imaging and therapy; diabetes imaging; and dualcompound imaging in cancer for SPECT/CT, SPECT/MRI, PET/CT, and PET/MRI. Information on Cell>Point’s product candidates and licenses, recent press releases, and patents and patent filings can be obtained through its website at www.cellpointweb.com. The Company has offices in Centennial, Colo., San Francisco and Houston.

Cell>Point and HYUN IMC Expand License in South Korea to Include Hanmi Pharmaceutical, Co., Ltd for Cancer and Heart Disease Imaging

Third License Completes the Company’s Initiative to Secure a Strong Pharmaceutical  Partner for the South Korean Market

CENTENNIAL, Colo., March 11, 2013—Cell>Point announced today that it entered into a license agreement on December 17,2012 with Hanmi Pharmaceutical Co., Ltd (Hanmi) who is headquartered in Seoul, Korea. The license agreement also includes HYUN IMC as a party (who Cell>Point previously entered into a license with in February 2012 and subsequently amended and restated the license agreement with HYUN IMC on December 4, 2012). The license agreement with Hanmi covers the kit manufacture, marketing and distribution of Cell>Point’s cancer and cardiology imaging product based on its Ethylenedicysteine‐Glucosamine (EC‐G) technology platform. The initial product will be technetium‐99m labeled EC‐G (99mTc‐EC‐G) for SPECT and SPECT/CT imaging. Downstream, the license agreement will cover gallium‐68 labeled EC‐G (68Ga‐EC‐G) for PET/CT imaging. In addition, Hanmi has been granted a Right of First Refusal regarding Cell>Point’s cold metallic therapeutic products Platinum‐EC‐G and 187Rhenium‐ EC‐G, and two imaging products, 99mTc‐EC‐Annexin V to image tumor cell apoptosis, and 99mTc‐EC‐Metronidazole to image tumor cell hypoxia.

Cell>Point receives upfront payments, milestone progress payments, and a royalty on
commercial sales.“We are pleased to associate with such an outstanding pharmaceutical company whose vision is to bring imaging technology to South Korea that has the potential to make high quality cancer imaging more affordable and accessible at a time when the cost of healthcare is becoming a national priority, as it is in many other countries around the world. In addition, Hanmi Pharmaceutical Co is committed to making available cardiovascular imaging technology that has the potential to increase diagnostic accuracy, drastically shorten the time that the patient has to devote to a cardiovascular study, and make the study considerably easier for the patient,” said Cell>Point CEO Greg Colip.
99mTc‐EC‐G, invented at The University of Texas M.D. Anderson Cancer Center and acquired by Cell>Point, is a target‐specific molecular imaging radiopharmaceutical that has moved into a Phase 3 lung cancer imaging trial and Phase 2 cardiology imaging trial.99mTc‐EC‐G is injected intravenously and then imaged using a Single Photon Emission Computed Tomography (SPECT) camera (sometimes referred to as a gamma camera) or a combination SPECT/Computed Tomography (SPECT/CT) camera system. The current standard of care in cancer molecular imaging is fluorine‐18 FluoroDeoxyGlucose (18F‐FDG) imaged using a combination Positron Emission Tomography /Computed Tomography (PET/CT) camera system.

99mTc‐EC‐G Phase 3 lung cancer imaging trial For the Phase 3 lung cancer study, all patients will be imaged with 99mTc‐EC‐G on SPECT/CT and separately imaged with 18F‐FDG on PET/CT cameras. Where combination SPECT/CT cameras are not available, a special workstation will be used to integrate the patient images taken from the stand‐alone SPECT and CT cameras. Using a workstation to integrate the images allows the medical site to take full advantage of 99mTc‐EC‐G without the need for a new combination SPECT/CT camera on the premises. This should significantly expand the utilization of the installed SPECT camera base in the United States and the rest of the world, which is lready
substantially greater than the PET and PET/CT camera base. The lung cancer trial will be followed by Phase 4 trials in lymphoma, breast, liver, colorectal, prostate, and head and neck cancers.

99mTc‐EC‐G Phase 2 cardiology imaging trial In a separate clinical trial, 99mTc‐EC‐G has moved from a Phase 1 to a Phase 2 cardiovascular imaging study. The product is the same as that used in the oncology trials. 99mTc‐EC‐G exhibits minimal uptake in the normal heart; however, it exhibits very high uptake in heart cells that are ischemic (i.e., deprivation of blood flow), such as from atherosclerotic heart disease. The Phase 2 cardiovascular trial involves patients who have suspected coronary artery disease and compares 99mTc‐EC‐G images of the heart with images obtained from the standard of care nuclear cardiology procedure, a full “stress/rest” Myocardial Perfusion Imaging (MPI) protocol.

One of the clinical objectives is to compare the results from the “rest” only portion of the 99mTc‐ EC‐G study to the results from the full “stress/rest” MPI study. Based on clinical evidence from the Phase 1 study, Cell>Point believes clinical information from the 99mTc‐EC‐G “rest” study has the potential for greater diagnostic accuracy in less study time than that required from conducting the full “stress/rest” MPI study. The standard MPI study uses either 99mTc‐sestamibi or thallium 201 for the “stress/rest” images. The traditional “stress/rest” MPI study can take up to 5 to 7 hours to complete, whereas the “rest” only 99mTc‐EC‐G study can be completed in 30 to 45 minutes. This has the potential to dramatically change the logistics of nuclear cardiovascular imaging by providing more comfort and convenience for the patient, by eliminating the need for a stress test and the shorter time required to complete the imaging.

About Cell>Point
Cell>Point is a commercialization‐stage biopharmaceutical company developing universal
molecular imaging agents and molecular therapeutics for the diagnosis, treatment and
treatment monitoring of cancer, heart, and other diseases. Cell>Point has exclusive license to five drug‐development platforms covering cancer imaging and therapy, cardiovascular imaging, high‐yield radio/chemotherapy delivery system for treating inoperable and unresectable tumors, neuroendocrine disease imaging and therapy, diabetes imaging, and dual compound imaging in cancer for SPECT/CT, SPECT/MRI, PET/CT, and PET/MRI, all from The University of Texas M.D. Anderson Cancer Center in Houston, a world leader in cancer research and care.Information on Cell>Point’s drug candidates and licenses, recent press releases, and patents and patent filings can be obtained through its website at www.cellpointweb.com. The company is headquartered in Centennial, Colo., and has additional offices in San Francisco and Houston.

About Hanmi Pharmaceutical Co., Ltd
Established in 1973, Hanmi Pharmaceuticals has risen to be one of the top 5 harmaceutical
companies in Korea, and has been the most R&D focused company with the highest R&D
investment for several years. Hanmi Pharmaceuticals has worldwide offices in major countries such as, but not limited to, China, Japan, Europe, and the U.S. The company’s long‐term strategy has been to remain highly flexible, to recognize the need to continuously change and adapt its market and development strategy from its beginnings as a generic pharmaceutical company to Incrementally Modified Drug and Fixed Dose Combination Drugs, and to new drug development including innovative small molecules and biologics. The company has more than 10 FDC pipelines including collaboration projects with Merck, Glaxo SmithKline and Sanofi. During the period of open innovation, Hanmi Pharmaceuticals made multiple strategic collaborations with multinational companies and biotech companies. The company is actively conducting clinical trials for new drug pipelines such as biobetter drugs with LAPSCOVERY (Long Acting Protein‐ Peptide Discovery Platform Technology) and small molecule oncology pipelines in global markets.

About HYUN IMC
HYUN IMC is a South Korean company with interests throughout the Pacific Rim. The company’s core business is in the manufacture and distribution of various medical isotope generators, the production and installation of hot cells, and trading in pharmaceutical raw materials. Through its affiliation with and support from Korean pharmaceutical companies, HYUN IMC made the decision to expand its nuclear medicine business by moving into radio pharmaceutical manufacturing and distribution.

Cardiology Imaging Technologies presents cardiology clinical trial data on EC-G at the American Society of Nuclear Cardiology 2012 Annual Conference

CENTENNIAL, Colo., September 11, 2012 – Cell>Point announced today that Cardiovascular Imaging Technologies presented a Phase 1b clinical trial abstract for its cardiology imaging agent, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glocosamine), used to image ischemic patients during rest and exercise stress testing at the American Society of Nuclear Cardiology 2012 Meeting on September 6, 2012.

http://www.cellpointweb.com/pdf/press/CellPoint-Press-Release-Sept-11-2012.pdf

See the Myocardial Uptake of a Novel Tc-99m Labeled Glucose diagram

Cell>Point to Present at the 26th Indian Cooperative Oncology Network (ICON) Meeting in Bengaluru, India

CENTENNIAL, Colo., March 17, 2012 – Cell>Point today that Company President David Rollo, M.D., Ph.D.,will present at the 26th Indian Oncology Network (ICON) Meeting in Bengaluru, India, On Saturday, March 27, 2012, at 10:45 a.m. local time. The ICON meeting will be held at the Crowne Plaza in Bengaluru.

http://www.cellpointweb.com/Press-Release-EC-G%20Cardio-1b-2-IND-Final.pdf

Cell>Point Announces Agreement with the FDA on a Special Protocol Assessment for the Phase 3 Technetium-99m-EC-G Lung Cancer Imaging Trial

CENTENNIAL, Colo., March 8, 2012 – Cell>Point, L.L.C , announced today that it received a letter from the U.S. Food and Drug Administration (FDA) indicating that agreement has been reached pursuant to a Special Protocol Assessment regarding the design of its Phase 3 pivotal clinical study in lung cancer.

http://www.cellpointweb.com/spa-press-release-march-8-2012.pdf

Cell>Point Executes Asia License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent, Technetium99mEC-G

CENTENNIAL, Colo., February 28, 2012 – Cell>Point announced today that it had entered into a licensing agreement for countries of the South Korea, Taiwan, Malaysia, Vietnam, and the Philippines with HYUN IMC Co.,Ltd., headquatered in Seoul, South Korea.

http://www.cellpointweb.com/PR-Feb-28-2012.pdf

CENTENNIAL, Colo., January 24, 2012—Cell>Point announced today that it has entered into a long-term collaboration agreement including product licenses for Brazil with MJM Productos Farmaceuticos e de Radioprotecao Ltda., or “Radiopharmacus.”

Cell>Point announced today that it has entered into a long-term collaboration agreement including product licenses for Brazil with MJM Productos Farmaceuticos e de Radioprotecao Ltda., or “Radiopharmacus.”
The agreement leads with Cell>Point’s cancer and cardiology molecular imaging agent—EC-G or, specifically, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine)—but covers the entire portfolio of products being developed by Cell>Point. EC-G has completed a U.S. Phase 2 clinical trial for non-small cell lung cancer diagnosis and staging, and a Phase 1 trial for coronary artery disease diagnosis.In addition to the exclusive right to manufacture and sell Cell>Point products in Brazil following regulatory approval, Radiopharmacus will also provide a range of services including commercial scale synthesis, cGMP (certified Good Manufacturing Practice) manufacturing, preclinical studies, clinical studies, and regulatory interface.
“We are very pleased to have a strategic partner in Brazil like Radiopharmacus,” said Greg Colip, Cell>Point chief executive officer.
“The broad scope of the relationship shouldhelp shorten the lead time to complete the chemistry, manufacturing and control process for each of our products, and allow us to explore the clinical feasibility of each product before ramping up clinical-development investment.”
Regarded as one of the most promising and attractive pharmaceutical markets in the Americas, the Brazilian market is the 11th largest globally at $17 billion dollars in annual sales, per Business Monitor International 2010 data. The Brazilian pharmaceutical market also has had consistently high growth over the last decade.
Radiopharmacus will manufacture EC-G product “kits” for Brazilian clinical studies and for sale in Brazil, following marketing approval by ANVISA, Brazil’s National Health Surveillance Agency.Radiopharmacus is affiliated with a leading Brazilian Contract Research Organization (CRO), which will oversee clinical trials conducted in Brazil.

CENTENNIAL, Colo., November 23, 2011

Cell>Point announced today that the University of Texas M.D. Anderson Cancer Center will present pre-clinical results on Cell>Point’s therapeutic, Platinum-EC-G, for Aggressive type-B Lymphoma at the 53rd American Society of Hematology Annual Meeting December 10-13, 2011

CENTENNIAL, Colo., June 6, 2011—Cell>Point announced today that it will present Phase 2 clinical trial results for its cancer molecular imaging agent, 99mTc-EC-G

http://www.cellpointweb.com/2011-SNM-Final.pdf

CENTENNIAL, Colo., March 18, 2010—Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan.

Embed Video

Cell>Point adds Dr. Wayne Yakes to Board of Advisors – 11/22/2010

CENTENNIAL, Colo., November 22, 2010 – Cell>Point is pleased to announce that Dr. Wayne Yakes has joined our Board of Advisors.  Dr. Yakes currently serves as the Director of the Vascular Malformation Center, Interventional Neuroradiology and Interventional Radiology – Swedish Medical Center, Englewood, Colorado.  Dr. Yakes is board certified in Radiology, Interventional Radiology and Neuroradiology with thirty one clinical professor appointments with university medical centers around the world including the University of Michigan Medical School, University of London Medical Center and Royal St. Albert’s University Medical Center.  Forty eight medical publications have been authored or co-authored by Dr. Yakes in addition to five hundred and eighty five medical presentations.  Dr. Yakes is a 1975 Distinguished Military Graduate and selected by Department of Army for the Military Intelligence Corps.  Dr. Yakes received both his Airborne Paratrooper Badge and Ranger Tab in 1974.  Dr. Yakes received his B.A. from Rice University in 1975 and M.D. from Creighton University School of Medicine in 1979.

Cell>Point to present at 52nd American Society of Hematology Annual Meeting December 4-7, 2010.

CENTENNIAL, Colo., December 1, 2010 – Dr. Lan V. Pham, Department of Hematophathology, The University of Texas M.D. Anderson Cancer Center, will be presenting the following paper titled “Metabolic Targeted Therapy for Aggressive B-cell Lymphomas: Evaluating Glucose Metabolism and the Potential of 187Rhenium-Ethylenedicysteine – N- AcetylGlucosamine (187Re-EC-G) for Therapy” at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida. 187Re-ECG utilizes Cell>Point’s intra-nuclear targeting technology EC-G.  The company successfully targeted lymphoma with EC-G in its Phase 1 99mTc-EC-G imaging trial conducted several years ago.  By substituting 99mTc with 187Re, the targeted diagnostic imaging agent is converted into a target specific therapeutic agent.  Key findings of the presentation show that 187Re-EC-G enters the nucleus and impacts the DNA which leads to lymphoma cell apoptosis.  An additional finding suggests that 187Re-Ec-G is an excellent potential candidate for targeted therapy in aggressive r/r lymphomas.